Antihypertensive Therapy in ADPKD
Use ACE inhibitors or ARBs as first-line antihypertensive therapy in all patients with ADPKD, regardless of kidney function stage. 1
First-Line Treatment
Renin-angiotensin system (RAS) inhibitors—specifically ACE inhibitors (ACEi) or angiotensin II receptor blockers (ARBs)—are the recommended first-line agents for blood pressure control in ADPKD 1. This recommendation is based on the pathophysiology of hypertension in ADPKD, where cyst expansion causes local renal ischemia and activates the renin-angiotensin-aldosterone system 2, 3.
Critical caveat: Never combine ACEi + ARB + direct renin inhibitor therapy 1. This combination increases risk without additional benefit.
Blood Pressure Targets (Age and CKD Stage-Specific)
The 2025 KDIGO guidelines provide specific BP targets based on age and kidney function 1:
For patients aged 18-49 years with CKD G1-G2:
- If BP >130/85 mm Hg: Target ≤110/75 mm Hg by home BP monitoring (if tolerated) 1
- If BP 110/75-130/85 mm Hg: Use individualized approach with shared decision-making 1
For patients aged ≥50 years and/or CKD G3-G5:
- Target mean systolic BP <120 mm Hg using standardized office BP measurement (if tolerated) 1
These aggressive targets are particularly important because optimal BP control dramatically reduces left ventricular hypertrophy risk—a major cardiovascular complication in ADPKD 3.
Why RAS Blockade is Superior
Network meta-analysis of randomized trials shows that while no antihypertensive class definitively slows eGFR decline more than others, ARBs ranked first in surrogate measures including eGFR preservation, reduced urinary albumin excretion, and systolic BP control 4. ACE inhibitors significantly reduced systolic BP, diastolic BP, mean arterial pressure, and left ventricular mass index compared to calcium channel blockers 4. Importantly, calcium channel blockers showed significantly increased urinary albumin excretion compared to ACEi or ARB 4.
Second-Line Agents
When BP remains uncontrolled on RAS blockade alone, the choice of second-line agent depends on individual patient factors 1. The guideline does not specify a preferred second agent, allowing flexibility based on comorbidities, side effects, and patient tolerance.
Monitoring Strategy
- Use standardized office BP measurement for all patients 1
- Add home BP monitoring or ambulatory BP monitoring to complement office readings 1
- Strongly consider ambulatory BP monitoring when: difficult-to-control BP, left ventricular hypertrophy present, proteinuria present, or declining kidney function with normal office BP (masked hypertension) 1
Resistant Hypertension (≥3 drugs)
Investigate for:
- Medication non-adherence first
- Secondary causes of hypertension 1
- High-grade proteinuria should prompt evaluation for coexisting kidney disease 1
Key Clinical Pitfalls
The evidence strongly supports RAS blockade as foundational therapy, but clinicians must avoid the temptation to combine multiple RAS inhibitors. While dual blockade was previously explored, it increases adverse events without improving outcomes 1. The aggressive BP targets in younger patients with preserved kidney function represent a paradigm shift from standard hypertension management and require careful patient counseling about potential side effects versus long-term cardiovascular and renal protection.